Which of the following is the first FDA-approved intravenous (IV) treatment for migraine prevention?
The active ingredient found in Vyepti is Eptinezumab-jjmr. It is the first FDA-approved intravenous (IV) treatment for migraine prevention.
Vyepti (Eptinezumab-jjmr) is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.
The recommended dose is 100 mg every 3 months; some patients may benefit from a dose of 300 mg.